Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …

Abstract Treatment with immune checkpoint inhibitors (ICPIs) extends survival in a
proportion of patients across multiple cancers. Tumor mutational burden (TMB)—the number …

Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in
patients with macroscopic stage III melanoma in the phase 1b OpACIN (NCT02437279) and …

MET-inhibitor and EGFR tyrosine kinase inhibitor (EGFR-TKI) combination therapy could
overcome acquired MET-mediated osimertinib resistance. We present the final phase Ib …

Cancer is still the leading cause of death globally. The approval of the therapeutic use of
monoclonal antibodies against immune checkpoint molecules, notably those that target the …

Introduction Hepatocellular carcinoma (HCC) represents the sixth most commonly
diagnosed malignancy worldwide, accounting for millions of deaths annually. Despite …

Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …

Circulating soluble programmed death-1 ligand (sPD-L1) is measurable in the serum of
cancer patients. This study aimed to investigate the significance of sPD-L1 in cancer patients …

Background: Despite an increasing understanding about tumor mutation burden (TMB) in
cancer immunity and cancer immunotherapy, the comprehensive cognition between TMB …

Tumor mutational burden (TMB) is a genomic biomarker that predicts favorable responses to
immune checkpoint inhibitors (ICIs). Here, we set out to assess the predictive value of TMB …